Moscow: Russia's single-dose COVID-19 vaccine, Sputnik Light, has demonstrated 70% efficacy against the Delta variant during the first three months after vaccination. The vaccine is more than 75% effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalisations, according to an analysis done by Gamaleya Center for Epidemiology and Microbiology.
Gamaleya Centre is a Russian medical research institute within Russia's Ministry of Health. Sputnik Light has demonstrated superior efficacy compared with some two-shot vaccines, which have shown a major decline in efficacy against the Delta variant to less than 50% five months after injection.
"Efficacy of the one-shot Sputnik Light vaccine as a booster against the Delta variant for other vaccines will be close to the efficacy against Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization," the Russian Direct Investment Fund said in a statement
The two-shot Sputnik V vaccine is authorized in 70 countries, with populations totalling over 4 billion people.
The Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V - the world's first registered vaccine against coronavirus
What is Sputnik Light?
As per Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik Light is one-shot COVID-19 vaccine with 80% efficacy — higher than many 2-shot vaccines.
The Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V - the world's first registered vaccine against coronavirus.
The one-shot Sputnik Light vaccine is authorized in more than 15 countries, with ongoing registration processes in another 30 countries.
Sputnik Light is a universal booster for other vaccines: positive data from clinical studies in Argentina and other countries demonstrate high safety and immunogenicity of Sputnik Light administered as a booster shot for vaccines of other producers.
Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.
The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization. No serious adverse events were registered after vaccination with Sputnik Light.
The single dose regiment allows for immunization of a larger number of people in a shorter time frame, furthering the fight against the pandemic during the acute phase.